Data from the first patients enrolled into Regenxbio's trial of its gene therapy for rare inherited disease mucopolysaccharidosis type I (MPS I) – also known as Hurler syndrome – has shown the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback